Effects of aspirin treatment on survival in non-insulin-dependent diabetic patients with coronary artery disease


      PURPOSE: The benefit of aspirin treatment among diabetic patients with chronic coronary artery disease is not well established. The purpose of this study was to assess the effect of aspirin on cardiac and total mortality in a large cohort of diabetic patients with established coronary artery disease and to compare it with the effect of aspirin in nondiabetic counterparts.
      PATIENTS AND METHODS: In this observational study among patients screened for participation in the Bezafibrate Infarction Prevention Study, the effects of aspirin treatment in 2,368 non-insulin-dependent diabetic patients with coronary artery disease were compared to those in 8,586 nondiabetic patients. Hazard ratios (HR) and 95% confidence intervals (CI) were estimated with proportional hazards models.
      RESULTS: Fifty-two percent of diabetic patients and 56% of nondiabetic patients reported aspirin therapy. After 5.1 ± 1.3 (mean ± SD) years of follow-up, the absolute benefit per 100 patients treated with aspirin was greater in diabetic patients than in nondiabetic patients (cardiac mortality benefit: 5.0 versus 2.1, and all-cause mortality benefit: 7.8 versus 4.1). Overall cardiac mortality among diabetic patients treated with aspirin was 10.9% versus 15.9% in the nonaspirin group (P <0.001), and all-cause mortality was 18.4% and 26.2% (P <0.001). After adjustment for possible confounders, treatment with aspirin was an independent predictor of reduced overall cardiac (HR = 0.8; 95% CI: 0.6–1.0) and all-cause mortality (HR = 0.8; 95% CI: 0.7–0.9) among diabetic patients, similar to those in nondiabetic patients.
      CONCLUSION: Treatment with aspirin was associated with a significant reduction in cardiac and total mortality among non-insulin-dependent diabetic patients with coronary artery disease. The absolute benefit of aspirin was greater in diabetic patients than in those without diabetes.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Aspirin Myocardial Infarction Study Research Group
        A randomized controlled trial of aspirin in persons recovered from myocardial infarction.
        JAMA. 1980; 243: 661-669
        • Ridker P.M.
        • Manson J.E.
        • Gazizno J.M.
        • Buring J.E.
        • Hennekens C.H.
        Low dose aspirin therapy for chronic stable angina.
        Ann Intern Med. 1991; 114: 835-839
        • Juul-Moller S.
        • Edvardsson N.
        • Jahnmatz B.
        • Rosen A.
        • Sorensen S.
        • Omblus R.
        • SAPAT (Swedish Angina Pectoris Aspirin Trial) Group
        Double blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris.
        Lancet. 1992; 340: 1421-1425
      1. Antiplatelet Trialist’s Collaboration. Collaborative overview of randomized trials of antiplatelet therapy-I: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81–106.

        • Goldstein R.E.
        • Andrews M.
        • Jackson Hall W.
        • Moss A.J.
        Marked reduction in long-term cardiac deaths with aspirin after a coronary event.
        J Am Coll Cardiol. 1996; 28: 326-330
        • Harpaz D.
        • Benderly M.
        • Goldbourt U.
        • Kishon Y.
        • Behar S.
        • for the Israeli BIP Study Group
        Effect of aspirin on mortality in women with symptomatic or silent myocardial ischemia.
        Am J Cardiol. 1996; 78: 1215-1219
        • Behar S.
        • Boyko V.
        • Reicher-Reiss H.
        • Goldbourt U.
        Ten-year survival after acute myocardial infarction.
        Am Heart J. 1997; 133: 290-296
        • Kannel W.B.
        • McGee D.L.
        Diabetes and glucose tolerance as risk factors for coronary artery disease.
        Diabetes Care. 1979; 2: 120-126
        • Betteridge D.J.
        • Zahavi J.
        • Jones N.A.G.
        • Shine B.
        • Bakkar W.
        • Galton D.S.
        Platelet function in diabetes in relation to complications, glycosylated hemoglobin and serum lipoproteins.
        Eur J Clin Invest. 1981; 111: 272-277
        • Lee H.
        • Paton C.R.
        • Passa P.
        • Caen J.P.
        Fibrinogen binding and ADP-induced aggregation in platelets from diabetic subjects.
        Thromb Res. 1981; 24: 143-150
        • Mustard J.F.
        • Packham M.A.
        Platelets and diabetes mellitus.
        NEJM. 1984; 311: 665-667
        • Di Minno G.
        • Silver M.J.
        • Cerbone A.M.
        • Riccardi G.
        • Rivellese A.
        • Mancini M.
        • Thiagarjan P.
        Increased binding of fibrinogen to platelets in diabetes.
        Blood. 1985; 65: 156-162
        • DiMinno G.
        • Silver M.J.
        • Cerbone A.M.
        • Riccardi G.
        • Rivellese A.
        • Mancini M.
        Platelet fibrinogen binding in diabetes mellitus.
        Diabetes. 1986; 35: 182-185
        • Hendra T.
        • Betteridge D.J.
        Platelet function, platelet prostanoids and vascular prostacyclin in diabetes mellitus.
        Prostagland Leukotr Essent Fatty Acids. 1989; 35: 197-212
        • Mori T.A.
        • Vandongen R.
        • Douglas A.J.
        • McCulloch R.K.
        • Burke V.
        Differential effect of aspirin on platelet aggregation in IDDM.
        Diabetes. 1992; 41: 261-266
      2. Colwell JA, Bingham SF, Abraira C, et al, and the Cooperative Study Group. Veterans Administration Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: II. Effects of aspirin and dipyridamole on atherosclerotic vascular disease rates. Diabetic Care 1986;9:140–148.

        • Sivenius J.
        • Laakso M.
        • Riekkinen Sr, P.
        • Smet S.
        • Lowenthal A.
        European Stroke Prevention Study.
        Stroke. 1992; 23: 851-854
        • ETDRS Investigators
        Aspirin effects on mortality and morbidity in patients with diabetes mellitus.
        JAMA. 1992; 268: 1292-1300
        • Goldbourt U.
        • Behar S.
        • Reicher-Reiss H.
        • et al.
        • for the Bezafibrate Infarction Prevention Study Group
        Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial).
        Am J Cardiol. 1993; 71: 909-915
      3. SAS Institute Inc., SAS Technical Report P-229, SAS/STAT Software: Changes and enhancements release 6.07, Cary, NC: SAS Institute, 1992:433–480.

        • Sagel J.
        • Calwell J.A.
        • Crook L.
        • Laimins M.
        Increased platelet aggregation in early diabetes mellitus.
        Ann Intern Med. 1975; 82: 735-738
        • Halushka P.V.
        • Lurie D.
        • Colwell J.A.
        Increased synthesis of prostaglandin-E-like material by platelets from patients with diabetes mellitus.
        NEJM. 1977; 297: 1306-1310
        • Halushka P.V.
        • Rogers R.C.
        • Loadholdt C.B.
        • Colwell J.A.
        Increased platelet thromboxane synthesis in diabetes mellitus.
        J Lab Clin Med. 1981; 97: 87-96
        • Davi G.
        • Catalano I.
        • Averna M.
        • et al.
        Increased thromboxane bio-synthesis and platelet function in type II diabetes mellitus.
        NEJM. 1990; 322: 1769-1774
        • Davi G.
        • Gresele P.
        • Violi F.
        • et al.
        Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease.
        Circulation. 1997; 96: 69-75
        • FitzGerald G.A.
        • Smith B.
        • Pedersen A.K.
        • Brash A.R.
        Increased probiosynthesis in patients with severe atherosclerosis and platelet activation.
        NEJM. 1984; 310: 1065-1068
        • DiMinno G.
        • Silver M.I.
        • Cerbone A.M.
        • Murphy S.
        Trial of repeated low-dose aspirin in diabetic angiopathy.
        Blood. 1986; 68: 886-891
        • ISIS-2 (Second International Study of Infarct Survival) Collaborative Group
        Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction.
        Lancet. 1988; ii: 349-360
        • The BARI Investigators
        Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI).
        Circulation. 1997; 96: 1761-1769
        • Ellis S.G.
        • Narins G.R.
        Problem of angioplasty in diabetics.
        Circulation. 1997; 96: 1707-1710